---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072046"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:56:48.356800+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics Q1 net loss $3.7M, cash $2.6M; advances ADC pipeline

## Summary
- Net loss from operations $3.7M in Q1 2025 vs $5.6M in Q1 2024; R&D spend down to $0.8M.
- Cash $2.6M as of March 31, 2025; March 2025 offering netted $6.0M, $4.0M received in April.
- Appointed Mark Kubik as Head of Business Development, Oncology to strengthen ADC expertise.
- Expects to present preclinical data for PH1-payload ADC at a scientific conference in H2 2025.
- Pipeline lead AKTX-101 (Trop2/PH1 ADC) advancing; out-licensing non-core assets for non-dilutive capital.

## SEC filing metadata
- accession: 0000950170-25-072046
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/0000950170-25-072046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017025072046/aktx-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072046
- JSON: https://secwatch.observer/filing/0000950170-25-072046.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.